AXNX News and Press, Axonics Modulation Technologies Inc. From 04/30/24

Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2024. “Our commercial team continued to e...

Boston Scientific Announces Results for First Quarter 2024 PR Newswire MARLBOROUGH, Mass. , April 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent o...

2024-04-09 21:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-05 06:42:07 ET Summary Boston Scientific expects 8-10% sales growth in their 2024-2026 guidance, which already includes short-term upsides such as FARAPULSE’s recent FDA approval. The legal clash between Axonics and Medtronic may endanger Boston Scientific's ability...

2024-04-04 08:09:04 ET Boston Scientific’s ( NYSE: BSX ) planned merger with Axonics ( NASDAQ: AXNX ) is now expected to close in the second half of the year after the companies received a request from the U.S. Federal Trade Commission (FTC) for additional informa...

2024-03-22 16:45:21 ET More on Axonics Modulation Technologies Medtronic claims upheld in two patents in spat with Axonics Boston Scientific pulls, refiles HSR notification for Axonics deal Seeking Alpha’s Quant Rating on Axonics Modulation Technologies ...

Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics’ merger agreement with Boston Scientific Corporation (NYSE: BSX). According to preliminary voting results from the special meeting of stockholders held earlier today, a majority of the shares of ...

Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two Medtronic patents that Axonics is contesting. The PTAB issued its decision with respect to Patent Nos. 8,626,314 (“the ...

2024-03-21 15:39:25 ET More on Medtronic, Axonics Medtronic: Undervalued Medical Devices Stock With Robust Demand And Strong Dividend Growth Medtronic: Its Recent Beat Proves That It Continues To Be A Rock Boston Scientific pulls, refiles HSR notification for Axonics...

2024-03-15 15:16:36 ET More on the markets Fairlead Strategies founder: This year is the year of the long-term turnarounds Inflation Is Not Running Hot S&P 500: Stay Invested, Cut Risk, And Be Ready To Buy The Dips The next Nvidia? Goldman Sachs spotlight...